New Molecule Outperforms Pancreatic Cancer Chemotherapy
A new molecule has outperformed standard chemotherapy in advanced pancreatic cancer trials. Patients receiving the new molecule survived more than 13 months on average, approximately double the survival time of the comparison group.
Topics
Developing
- 883d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 883d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 883d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 883d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Bluesky Social
“A new molecule outperformed standard chemotherapy in advanced pancreatic cancer. In the trial, half the patients survived more than 13 months, about double the comparison group.”
GDELT Global Events
“做强科技金融 _ 观点评论 _ 财经 _ 中金在线 宏盛华源 ( 601096 ): 宏盛华源关于中电装财务有限公司风险持续评估报告 - CFi . CN 中财网 堵疏结合打击金融 黑灰产 _ 观点评论 _ 财经 _ 中金在线”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade